PT J
AU Lai, FTT
   Huang, L
   Chui, CSL
   Wan, EYF
   Li, X
   Wong, CKH
   Chan, EWW
   Ma, TT
   Lum, DH
   Leung, JCN
   Luo, H
   Chan, EWY
   Wong, ICK
AF Lai, Francisco Tsz Tsun
   Huang, Lei
   Chui, Celine Sze Ling
   Wan, Eric Yuk Fai
   Li, Xue
   Wong, Carlos King Ho
   Chan, Edward Wai Wa
   Ma, Tiantian
   Lum, Dawn Hei
   Leung, Janice Ching Nam
   Luo, Hao
   Chan, Esther Wai Yin
   Wong, Ian Chi Kei
TI Multimorbidity and adverse events of special interest associated with
   Covid-19 vaccines in Hong Kong
SO NATURE COMMUNICATIONS
LA English
DT Article
ID VACCINATION; CARE
AB Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as >= 2 chronic conditions. We examine the potential additional risk of adverse events 28 days after the first dose of CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database with population-based vaccination records in Hong Kong, we analyze a retrospective cohort of patients with chronic conditions. Thirty adverse events of special interest according to the World Health Organization are examined. In total, 883,416 patients are included and 2,807 (0.3%) develop adverse events. Results suggest vaccinated patients have lower risks of adverse events than unvaccinated individuals, multimorbidity is associated with increased risks regardless of vaccination, and the association of vaccination with adverse events is not modified by multimorbidity. To conclude, we find no evidence that multimorbidity imposes extra risks of adverse events following Covid-19 vaccination.
   Adverse events resulting from COVID-19 vaccination are a public health concern and it is not known whether pre-existing conditions may impose an increased risk. Here, using electronic health records from Hong Kong, the authors show that adverse events are rare for all groups, and there is no evidence of risk modification due to multimorbidity.
C1 [Lai, Francisco Tsz Tsun; Huang, Lei; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Chan, Edward Wai Wa; Ma, Tiantian; Lum, Dawn Hei; Leung, Janice Ching Nam; Chan, Esther Wai Yin; Wong, Ian Chi Kei] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China.
   [Lai, Francisco Tsz Tsun; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Li, Xue; Wong, Carlos King Ho; Ma, Tiantian; Leung, Janice Ching Nam; Chan, Esther Wai Yin; Wong, Ian Chi Kei] Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth D24H, Hong Kong Sci Pk, Hong Kong, Peoples R China.
   [Chui, Celine Sze Ling] Univ Hong Kong, Li Ka Shing Fac Med, Sch Nursing, Hong Kong, Peoples R China.
   [Chui, Celine Sze Ling] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Wan, Eric Yuk Fai; Wong, Carlos King Ho] Univ Hong Kong, Li Ka Shing Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China.
   [Li, Xue] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China.
   [Luo, Hao] Univ Hong Kong, Fac Social Sci, Dept Social Work & Social Adm, Hong Kong, Peoples R China.
   [Luo, Hao] Univ Hong Kong, Fac Engn, Dept Comp Sci, Hong Kong, Peoples R China.
   [Wong, Ian Chi Kei] UCL, Sch Pharm, Res Dept Practice & Policy, London, England.
RP Wong, ICK (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China.; Wong, ICK (corresponding author), Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth D24H, Hong Kong Sci Pk, Hong Kong, Peoples R China.; Wong, ICK (corresponding author), UCL, Sch Pharm, Res Dept Practice & Policy, London, England.
EM wongick@hku.hk
RI Lai, Francisco TT/F-3842-2019; Wong, Carlos King-ho/B-4322-2011
OI Lai, Francisco TT/0000-0002-9121-1959; Wong, Carlos
   King-ho/0000-0002-6895-6071
FU Food and Health Bureau, Government of the Hong Kong Special
   Administrative Region of China [COVID19F01]
FX This study was funded by a research grant from the Food and Health
   Bureau, Government of the Hong Kong Special Administrative Region of
   China to Prof. Ian Chi Kei Wong (reference COVID19F01). We thank Mr.
   Joseph Blais for language proofreading this manuscript.
CR Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475
   Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2
   Brilleman SL, 2013, FAM PRACT, V30, P172, DOI 10.1093/fampra/cms060
   Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295
   Centre for Health Protection, INT GUID NOT COMM ME
   Centre for Health Protection, HONG KONG VACC DASHB
   Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546
   Chung GKK, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158168
   Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765
   de Simone G, 2021, EUR HEART J-CARD PHA, V7, pE77, DOI 10.1093/ehjcvp/pvab036
   Hanlon P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018404
   Hong Kong Government, COVID 19 VACC PROGR
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Incalzi RA, 2021, VACCINE, V39, P2325, DOI 10.1016/j.vaccine.2021.03.066
   Kwok KO, 2021, EMERG INFECT DIS, V27, P1802, DOI 10.3201/eid2707.210054
   Lai FTT, 2022, PSYCHOL MED, V52, P283, DOI 10.1017/S0033291720001920
   Lai FTT, 2019, EUR J INTERN MED, V61, P103, DOI 10.1016/j.ejim.2018.12.001
   Lau WCY, 2017, JAMA-J AM MED ASSOC, V317, P1151, DOI 10.1001/jama.2017.1363
   Leung GM, 2009, HEALTH ECON, V18, P37, DOI 10.1002/hec.1342
   Li X., ANN RHEUM DIS, DOI [10.1136/annrheumdis-2021-221571(2021), DOI 10.1136/ANNRHEUMDIS-2021-221571(2021)]
   Li XT, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1435
   Man KKC, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2350
   Marengoni A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1059
   Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8
   Montgomery J, 2021, JAMA CARDIOL, V6, P1202, DOI 10.1001/jamacardio.2021.2833
   Nguyen Hai, 2019, J Comorb, V9, p2235042X19870934, DOI 10.1177/2235042X19870934
   Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5
   Patone M, 2021, NAT MED, V27, P2144, DOI 10.1038/s41591-021-01556-7
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Revon-Riviere G, 2021, EUR J CANCER, V154, P30, DOI 10.1016/j.ejca.2021.06.002
   Salah HM, 2021, AM J CARDIOL, V157, P146, DOI 10.1016/j.amjcard.2021.07.009
   Sturkenboom M, COVERAGE COVID 19 VA
   Su S, 2021, NAT REV MICROBIOL, V19, P211, DOI 10.1038/s41579-020-00462-y
   Takuva S, 2021, NEW ENGL J MED, V385, P570, DOI 10.1056/NEJMc2107920
   Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X
   Tonelli M, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0155-5
   Tsai R., JMIR PUBLIC HLTH SUR, DOI [10.2196/29872(2021, DOI 10.2196/29872(2021]
   Wang JT, 2021, J HEPATOL, V75, P439, DOI 10.1016/j.jhep.2021.04.026
   Wong AYS, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6926
   World Health Organization, 2020, BACKGR PAP COV 19 DI
   Wu QH, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02059-5
   Yeoh EK, 2020, HEALTH POLICY, V124, P189, DOI 10.1016/j.healthpol.2019.12.009
   Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344
   Zhao QY, 2017, J CAUSAL INFERENCE, V5, DOI 10.1515/jci-2016-0010
NR 44
TC 5
Z9 5
U1 3
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 20
PY 2022
VL 13
IS 1
AR 411
DI 10.1038/s41467-022-28068-3
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YK8QB
UT WOS:000745469500002
PM 35058463
OA Green Published, gold
DA 2022-05-16
ER

PT J
AU Nadimuthu, LPR
   Victor, K
AF Nadimuthu, Lalith Pankaj Raj
   Victor, Kirubakaran
TI Environmental friendly micro cold storage for last-mile Covid-19 vaccine
   logistics
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article
DE Covid-19 vaccine; Last-mile vaccine logistics; Micro cold storage; Solar
   photovoltaics; Climate change mitigation; Carbon emission reduction
ID COOLER; ENERGY
AB Globally, vaccination plays a vital role in controlling the Covid-19 pandemic. However, the cold supply chain is essential for vaccine storage and logistics services. In a country like India, the last-mile logistics of vaccines is a challenging task. The cold chain is indispensable for the Covid-19 vaccine drive to the rural areas. The demand for cold storage increases rapidly due to the rapid Covid-19 vaccine drive. The conventional cold storage facility has a more significant threat to the grid power quality and environmental impacts. The energy demand and greenhouse gas emission of traditional cold storage lead to global warming. The micro cold storage facility has to be developed rapidly to accelerate the vaccine drive to the last mile of the county with reliable and affordable energy sources. In addition, climate change mitigation is ensured by the renewable energy utilization in the Covid-19 vaccine drive. The proposed novel micro cold storage aims to be silent, clean, mobile, without moving parts, and reliable for the last-mile vaccine logistics as a vaccine carrier to the remote rural areas. This paper deals with the novel design, development, and experimental investigation of solar photovoltaic powered thermoelectric-based micro cold storage as a Covid-19 vaccine carrier for rural areas. The design consideration of Covid-19 vaccine storage has been reported. The experimental results ensure the World Health Organization recommended vaccine storage (i.e., vaccine carrier) temperature range of +2 to +8 degrees C. Therefore, green energy and refrigeration system provide environmental sustainability by mitigating 700kg of annual carbon emission.
C1 [Nadimuthu, Lalith Pankaj Raj; Victor, Kirubakaran] Gandhigram Rural Inst Deemed Univ, Ctr Rural Energy, Gandhigram 624302, Tamil Nadu, India.
RP Nadimuthu, LPR (corresponding author), Gandhigram Rural Inst Deemed Univ, Ctr Rural Energy, Gandhigram 624302, Tamil Nadu, India.
EM lpraj1995@gmail.com
RI Nadimuthu, Lalith Pankaj Raj/ABA-6826-2020; V, Kirubakaran/AAA-3938-2020
OI Nadimuthu, Lalith Pankaj Raj/0000-0002-0387-4120; V,
   Kirubakaran/0000-0001-7160-4758
FU Department of Science and Technology (DST), Government of India
   [IF180435]; All India Council for Technical Education (AICTE)
   [9-41/RIFD/MODROB/Policy-1/2017-18]
FX The authors gratefully acknowledge the Department of Science and
   Technology (DST), Government of India, for support under the DST-INSPIRE
   Fellowship Scheme (ID No: IF180435). Also, acknowledge the funding
   received from the All India Council for Technical Education (AICTE)
   under the Modernization and Removal of Obsolescence (MODROBS) scheme
   (AICTE File No. 9-41/RIFD/MODROB/Policy-1/2017-18 Dt. 26.03.2019).
CR Arputham S., 2021, THERM SCI THERM SCI, V298, DOI [10.2298/TSCI201110298S, DOI 10.2298/TSCI201110298S]
   Benhadid-Dib S, 2012, ENRGY PROCED, V18, P807, DOI 10.1016/j.egypro.2012.05.096
   Bharatbiotech, 2020, COVAXIN IND 1 IND CO
   Cai Y, 2016, ENERG CONVERS MANAGE, V124, P203, DOI 10.1016/j.enconman.2016.07.011
   Dai DM, 2021, ADV DIFFER EQU-NY, V2021, DOI 10.1186/s13662-020-03173-z
   Dimri N, 2017, ENERG CONVERS MANAGE, V146, P68, DOI 10.1016/j.enconman.2017.05.017
   Gianfredi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060574
   GOI-MOP, 2018, CO 2 BAS DAT IND POW
   government of India M of H and FW, 2020, COVID 19 VACC OP GUI
   Government of India Ministry of Health & Family Welfare, 2016, HDB VACC COLD CHAIN
   Hagenkamp M, 2022, INT J ENERGY ENVIR E, V13, P241, DOI 10.1007/s40095-021-00424-x
   Healthcare Global, CHALL VACC DISTR AFF
   Hindu BL-T, IND CAN MEET COVID V
   India C, 2016, COOLING INDIA MONTHL
   Jiang P, 2021, ENERGY, V235, DOI 10.1016/j.energy.2021.121315
   Kirubakaran, 2019, WASTE VALORISATION R, P349
   Kumar VM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00327-2
   Lalith Pankaj, 2018, INT J ENG TECHNOLOGY, V7, DOI [10.14419/ijet.v7i23314832, DOI 10.14419/IJET.V7I2.33.14832]
   Raj GNLP, 2021, INT J PHOTOENERGY, V2021, DOI 10.1155/2021/6651717
   Lee TH, 2021, NEW ENGL J MED, V384, P685, DOI 10.1056/NEJMp2100574
   Marathe, 2021, TRANSP RES INTERDISC, V10, DOI DOI 10.1016/J.TRIP.2021.100339
   Marimuthu C, 2013, RENEW SUST ENERG REV, V23, P80, DOI 10.1016/j.rser.2013.02.045
   Marlow Industries I, THERM COOL SYST DES
   Mirmanto M, 2019, ENG SCI TECHNOL, V22, P177, DOI 10.1016/j.jestch.2018.09.006
   Nadimuthu LPR, 2021, IEEE ACCESS, V9, P146959, DOI 10.1109/ACCESS.2021.3123153
   Nadimuthu LPR, 2021, PROC INTEGR OPTIM, V5, P975, DOI 10.1007/s41660-021-00194-3
   Nadimuthu LPR, 2021, ENVIRON SCI POLLUT R, V28, P34278, DOI 10.1007/s11356-021-12894-x
   Ngcobo MEK, 2012, INT J REFRIG, V35, P445, DOI 10.1016/j.ijrefrig.2011.11.008
   Our World in Data, 2021, COR COVID 19 HOSP ST
   Padmavathy SR, 2021, ENVIRON SCI POLLUT R, DOI 10.1007/s11356-021-15875-2
   Raj GNLP, 2018, 2018 4TH INTERNATIONAL CONFERENCE ON ELECTRICAL ENERGY SYSTEMS (ICEES), P726, DOI 10.1109/ICEES.2018.8442352
   Raj N., THERM SCI, V301, DOI [10.2298/TSCI201211301N, DOI 10.2298/TSCI201211301N, 10.2298/ TSCI201211301N]
   RetailerTraining N, PROGR 2021 KNOW YOUR
   Ricco M, 2021, INFECT DIS NOW, V51, P402, DOI 10.1016/j.idnow.2021.03.001
   Saif A, 2016, EUR J OPER RES, V251, P274, DOI 10.1016/j.ejor.2015.10.056
   Sarwar S, 2021, J ENVIRON HEALTH SCI, V19, P1513, DOI 10.1007/s40201-021-00707-9
   Segarra M, 2015, MATER TODAY-PROC, V2, P858, DOI 10.1016/j.matpr.2015.05.111
   Selvaraj DA, 2021, INT J PHOTOENERGY, V2021, DOI 10.1155/2021/6655113
   Selvaraj DA, 2021, ENVIRON SCI POLLUT R, V28, P34248, DOI 10.1007/s11356-020-11214-z
   Sevindir MK, 2017, RENEW ENERG, V113, P74, DOI 10.1016/j.renene.2017.05.070
   Shaik SV, 2020, ENVIRON SCI POLLUT R, V27, P41415, DOI 10.1007/s11356-020-09478-6
   Shaik SV, 2020, P I MECH ENG C-J MEC, V234, P914, DOI 10.1177/0954406219884968
   SPUTNIK V, 2021, AB VACC OFF WEBS COV
   Sun Xu, 2021, Transp Res Interdiscip Perspect, V11, P100453, DOI 10.1016/j.trip.2021.100453
   Team SAA, YOURSTORY COM
   Vigneshwari CA, 2016, 2016 INTERNATIONAL CONFERENCE ON ENERGY EFFICIENT TECHNOLOGIES FOR SUSTAINABILITY (ICEETS), P239, DOI 10.1109/ICEETS.2016.7582933
   Waheed R, 2018, J CLEAN PROD, V172, P4231, DOI 10.1016/j.jclepro.2017.10.287
   Wang Y, 2019, SUSTAIN CITIES SOC, V49, DOI 10.1016/j.scs.2019.101599
   World Health Organization, 2015, IMM PRACT
   Xu XF, 2018, INT J ENERG RES, V42, P4429, DOI 10.1002/er.4187
   Zhao CJ, 2016, APPL ENERG, V168, P314, DOI 10.1016/j.apenergy.2016.01.101
NR 51
TC 0
Z9 0
U1 29
U2 29
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD APR
PY 2022
VL 29
IS 16
BP 23767
EP 23778
DI 10.1007/s11356-021-17584-2
EA NOV 2021
PG 12
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA 0H8WJ
UT WOS:000721662400006
PM 34816344
OA Bronze, Green Published
DA 2022-05-16
ER

PT J
AU Crommelin, DJA
   Volkin, DB
   Hoogendoorn, KH
   Lubiniecki, AS
   Jiskoot, W
AF Crommelin, Daan J. A.
   Volkin, David B.
   Hoogendoorn, Karin H.
   Lubiniecki, Anthony S.
   Jiskoot, Wim
TI The Science is There: Key Considerations for Stabilizing Viral
   Vector-Based Covid-19 Vaccines
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Editorial Material
DE Covid-19; Formulation; Freeze drying; Live attenuated virus; Shelf life;
   Stability; Storage; Vaccine; Viral vector
ID LIQUID FORMULATIONS; COLD CHAIN; LIVE; MEASLES; INFECTIVITY
AB Once Covid-19 vaccines become available, 5-10 billion vaccine doses should be globally distributed, stored and administered. In this commentary, we discuss how this enormous challenge could be addressed for viral vector-based Covid-19 vaccines by learning from the wealth of formulation development experience gained over the years on stability issues related to live attenuated virus vaccines and viral vector vaccines for other diseases. This experience has led -over time- to major improvements on storage temperature, shelf-life and in-use stability requirements. First, we will cover work on 'classical' live attenuated virus vaccines as well as replication competent viral vector vaccines. Subsequently, we address replication deficient viral vector vaccines. Freeze drying and storage at 2-8 degrees C with a shelf life of years has become the norm. In the case of pandemics with incredibly high and urgent product demands, however, the desire for rapid and convenient distribution chains combined with short end-user storage times require that liquid formulations with shelf lives of months stored at 2-8 degrees C be considered. In confronting this "perfect storm" of Covid-19 vaccine stability challenges, understanding the many lessons learned from decades of development and manufacturing of live virus-based vaccines is the shortest path for finding promising and rapid solutions. (c) 2020 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Crommelin, Daan J. A.] Univ Utrecht, Dept Pharmaceut, Fac Sci, Utrecht, Netherlands.
   [Volkin, David B.] Univ Kansas, Dept Pharmaceut Chem, Vaccine Analyt & Formulat Ctr, Lawrence, KS 66045 USA.
   [Hoogendoorn, Karin H.] Lonza BV, Preclin Serv Cell & Gene Therapy, Maastricht, Netherlands.
   [Lubiniecki, Anthony S.] AL Associates LLC, W Chester, PA USA.
   [Jiskoot, Wim] Leiden Univ, Leiden Acad Ctr Drug Res, Div BioTherapeut, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.
RP Jiskoot, W (corresponding author), Leiden Univ, Leiden Acad Ctr Drug Res, Div BioTherapeut, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.
EM w.jiskoot@lacdr.leidenuniv.nl
RI Jiskoot, Wim/A-6877-2016
OI Jiskoot, Wim/0000-0002-1012-3456
CR Burke CJ, 1999, CRIT REV THER DRUG, V16, P1
   Burke RM, 2019, CURR OPIN INFECT DIS, V32, P435, DOI 10.1097/QCO.0000000000000572
   Evans RK, 2004, J PHARM SCI-US, V93, P2458, DOI 10.1002/jps.20157
   Fedosyuk S, 2019, VACCINE, V37, P6951, DOI 10.1016/j.vaccine.2019.04.056
   FERRIS NP, 1990, J VIROL METHODS, V29, P43, DOI 10.1016/0166-0934(90)90006-2
   Gray GC, 2018, PLOTKINS VACCINES
   Hansen LJJ, 2015, VACCINE, V33, P5507, DOI 10.1016/j.vaccine.2015.08.085
   Juan-Giner A, 2020, VACCINE, V38, P2473, DOI 10.1016/j.vaccine.2020.02.005
   Kang MS, 2010, POULTRY SCI, V89, P1167, DOI 10.3382/ps.2009-00620
   Kumru OS, 2018, J PHARM SCI-US, V107, P2764, DOI 10.1016/j.xphs.2018.07.010
   Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007
   Lovalenti PM, 2016, PHARM RES-DORDR, V33, P1144, DOI 10.1007/s11095-016-1860-1
   Naik SP, 2017, VACCINE, V35, P2962, DOI 10.1016/j.vaccine.2017.04.025
   Patel A, 2018, VACCINE, V36, P3169, DOI 10.1016/j.vaccine.2017.04.086
   Prausnitz MR, 2020, CURR OPIN VIROL, V41, P68, DOI 10.1016/j.coviro.2020.05.005
   Reinauer EB, 2020, J PHARM SCI-US, V109, P818, DOI 10.1016/j.xphs.2019.10.063
   Schlehuber LD, 2011, VACCINE, V29, P5031, DOI 10.1016/j.vaccine.2011.04.079
   Shokri S, 2019, J VIROL METHODS, V264, P18, DOI 10.1016/j.jviromet.2018.08.013
   SOOD DK, 1993, VACCINE, V11, P1124, DOI 10.1016/0264-410X(93)90073-7
   Tlaxca JL, 2015, ADV DRUG DELIVER REV, V93, P56, DOI 10.1016/j.addr.2014.10.002
   Zhai SL, 2004, BIOTECHNOL PROGR, V20, P1113, DOI 10.1021/bp034362x
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 22
TC 13
Z9 13
U1 4
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD FEB
PY 2021
VL 110
IS 2
BP 627
EP 634
DI 10.1016/j.xphs.2020.11.015
EA JAN 2021
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA PS7SV
UT WOS:000608126900010
PM 33242452
OA Green Published, Bronze
DA 2022-05-16
ER

PT J
AU Pratama, NR
   Wafa, IA
   Budi, DS
   Putra, M
   Wardhana, MP
   Wungu, CDK
AF Pratama, Nando Reza
   Wafa, Ifan Ali
   Budi, David Setyo
   Putra, Manesha
   Wardhana, Manggala Pasca
   Wungu, Citrawati Dyah Kencono
TI mRNA Covid-19 vaccines in pregnancy: A systematic review
SO PLOS ONE
LA English
DT Review
ID HERD-IMMUNITY; TRANSPLACENTAL TRANSFER; ANTIBODIES; INFECTION
AB Objective
   Pregnancy is a known risk factor for severe Coronavirus disease 2019. It is important to develop safe vaccines that elicit strong maternal and fetal antibody responses.
   Methods
   Registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the European Union Clinical Trial Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, Springer, medRxiv, and bioRxiv) were systematically searched in June 20-22, 2021, for research articles pertaining to Covid-19 and pregnancy. Manual searches of bioRxiv and medRxiv were also conducted. Inclusion criteria were studies that focused on Covid-19 vaccination among pregnant women, while review articles and non-human studies were excluded. Infection rate, maternal antibody response, transplacental antibody transfer, and adverse events were described.
   Results
   There were 13 observational studies with a total of 48,039 pregnant women who received mRNA vaccines. Of those, three studies investigated infection rate, six studies investigated maternal antibody response, seven studies investigated antibody transfer, three studies reported local adverse events, and five studies reported systemic adverse events. The available data suggested that the mRNA-based vaccines (Pfizer-BioNTech and Moderna) can prevent future SARS-CoV-2 infection. These vaccines did not show clear harm in pregnancy. The most commonly encountered adverse reactions were pain at the injection site, fatigue, and headache, but these were transient. Antibody responses were rapid after the first vaccine dose. After the booster, antibody responses were stronger and associated with better transplacental antibody transfer. Longer intervals between first vaccination dose and delivery were also associated with higher antibody fetal IgG and a better antibody transfer ratio.
   Conclusions
   The SARS-CoV-2 mRNA vaccines are encouraged for pregnancy. These vaccines can be a safe option for pregnant women and their fetuses. Two vaccine doses are recommended for more robust maternal and fetal antibody responses. Longer latency is associated with higher fetal antibody responses. Further research about its long-term effect on pregnancy is needed.
C1 [Pratama, Nando Reza; Wafa, Ifan Ali; Budi, David Setyo] Univ Airlangga, Fac Med, Surabaya, Indonesia.
   [Putra, Manesha] Univ Colorado, Dept Obstet & Gynecol, Div Maternal Fetal Med, Anschutz Sch Med, Aurora, CO USA.
   [Wardhana, Manggala Pasca] Univ Airlangga, Dr Soetomo Gen Hosp, Fac Med, Dept Obstet & Gynecol, Surabaya, Indonesia.
   [Wungu, Citrawati Dyah Kencono] Univ Airlangga, Fac Med, Dept Physiol & Med Biochem, Surabaya, Indonesia.
   [Wungu, Citrawati Dyah Kencono] Univ Airlangga, Inst Trop Dis, Surabaya, Indonesia.
RP Wungu, CDK (corresponding author), Univ Airlangga, Fac Med, Dept Physiol & Med Biochem, Surabaya, Indonesia.; Wungu, CDK (corresponding author), Univ Airlangga, Inst Trop Dis, Surabaya, Indonesia.
EM citrawati.dyah@fk.unair.ac.id
RI ; Wardhana, Manggala Pasca/AAM-5919-2021
OI PRATAMA, NANDO REZA/0000-0001-5627-7525; Budi, David
   Setyo/0000-0002-0317-6402; Wardhana, Manggala Pasca/0000-0001-8013-4639;
   Kencono Wungu, Citrawati Dyah/0000-0001-5180-957X
CR Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974
   Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7
   Atyeo C, 2021, CELL, V184, P628, DOI 10.1016/j.cell.2020.12.027
   Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389
   Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011
   Beharier O, 2021, J CLIN INVEST, V131, DOI [10.1172/JCI154834, 10.1172/JCI150319]
   Bian LL, 2021, EXPERT REV VACCINES, V20, P365, DOI 10.1080/14760584.2021.1903879
   Boehm E, 2021, CLIN MICROBIOL INFEC, V27, P1109, DOI 10.1016/j.cmi.2021.05.022
   Castanha PMS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007246
   Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563
   Cuningham W, 2019, INFLUENZA OTHER RESP, V13, P438, DOI 10.1111/irv.12649
   Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
   Edlow AG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.30455
   Giles ML, 2019, HUM VACC IMMUNOTHER, V15, P687, DOI 10.1080/21645515.2018.1540807
   Gill L, 2021, OBSTET GYNECOL, V137, P894, DOI 10.1097/AOG.0000000000004367
   Goldshtein I, 2021, JAMA-J AM MED ASSOC, V326, P728, DOI 10.1001/jama.2021.11035
   Gomez CE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030243
   Goncalves G, 1999, EPIDEMIOL INFECT, V122, P273, DOI 10.1017/S0950268899002046
   Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023
   Griffith BC, 2020, VACCINE, V38, P8040, DOI 10.1016/j.vaccine.2020.09.076
   Haghpanah F, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100863
   Heininger U, 2009, PEDIATR INFECT DIS J, V28, P443, DOI 10.1097/INF.0b013e318193ead7
   Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jennewein MF, 2019, CELL, V178, P202, DOI 10.1016/j.cell.2019.05.044
   Joanna Briggs Institute, CHECKL SYST REV RES
   Kadali RAK, 2021, AM J OBSTET GYNECOL, V225, P458, DOI 10.1016/j.ajog.2021.06.007
   Kann L, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6506a1
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Nasreen S., 2021, EFFECTIVENESS COVID, DOI 10.1101/2021.06.28.21259420
   Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n71
   Paul G, 2021, BMC PEDIATR, V21, DOI 10.1186/s12887-021-02618-y
   Perret C, 2005, J INFECTION, V51, P287, DOI 10.1016/j.jinf.2004.10.003
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Prabhu M, BIORXIV PREPRINT, V2021, DOI [10.1101/2021.04.05.438524, DOI 10.1101/2021.04.05.438524]
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Riley LE, 2021, NEW ENGL J MED, V384, P2342, DOI 10.1056/NEJMe2107070
   Rottenstreich A, 2021, CLIN INFECT DIS, V73, P1909, DOI 10.1093/cid/ciab266
   Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6
   Shakib JH, 2013, J PEDIATR-US, V163, P1422, DOI 10.1016/j.jpeds.2013.06.021
   Shanes ED, 2021, OBSTET GYNECOL, V138, P281, DOI 10.1097/AOG.0000000000004457
   Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1
   Shimabukuro TT, 2021, NEW ENGL J MED, V384, P2273, DOI 10.1056/NEJMoa2104983
   Starr TN, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100255
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Theiler RN, 2021, AM J OBST GYNEC MFM, V3, DOI 10.1016/j.ajogmf.2021.100467
   Van Spall HGC, 2021, EUR HEART J, V42, P2724, DOI 10.1093/eurheartj/ehab103
   Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]
   Wardhana MP, 2021, PAK J MED HEALTH SCI, V15, P508
   Wells G., NEWCASTLE OTTAWA SCA
   Xia YQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.547314
   Yanes-Lane M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241536
   Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3
NR 53
TC 3
Z9 3
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 2
PY 2022
VL 17
IS 2
AR e0261350
DI 10.1371/journal.pone.0261350
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0D3HO
UT WOS:000775890100009
PM 35108277
OA gold, Green Published
DA 2022-05-16
ER

PT J
AU Sznajder, KK
   Kjerulff, KH
   Wang, M
   Hwang, W
   Ramirez, SI
   Gandhi, CK
AF Sznajder, Kristin K.
   Kjerulff, Kristen H.
   Wang, Ming
   Hwang, Wenke
   Ramirez, Sarah, I
   Gandhi, Chintan K.
TI Covid-19 vaccine acceptance and associated factors among pregnant women
   in Pennsylvania 2020
SO PREVENTIVE MEDICINE REPORTS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Immunization during pregnancy; Vaccine-preventable
   diseases; Pennsylvania; Pregnant Women; Vaccination
ID UNITED-STATES; IMMUNIZATION PRACTICES; INFLUENZA VACCINATION;
   ADVISORY-COMMITTEE; DETERMINANTS; PERTUSSIS; FEVER; TRUST; RISK
AB Data on factors associated with vaccine acceptance among pregnant women are critical to the rapid scale up of interventions to improve vaccine uptake. When COVID-19 vaccines were still in the testing phases of research, we surveyed pregnant women accessing prenatal care at an academic medical institution in Central Pennsylvania, United States to examine factors associated with vaccine acceptance. Willingness to receive a COVID-19 vaccine once a vaccine became available was asked as part of an ongoing study on the COVID-19 pandemic and pregnancy (n = 196). Overall, 65% of women reported they would be willing or somewhat willing to receive the COVID-19 vaccine. Women who had received an influenza vaccine within the past year were more likely to be willing to receive the COVID-19 vaccine than women who had never received an influenza vaccine or those who received it over one year ago (aOR 4.82; 95% CI 2.17, 10.72). Similarly, women who were employed full-time were more willing to receive the COVID-19 vaccine than women who were not employed full time (aOR 2.22; 95% CI 1.02, 4.81), and women who reported feeling overloaded were more willing to receive the COVID-19 vaccine than women who did not feel overloaded (aOR 2.18; 95% CI 1.02, 4.68). Our findings support the need to increase vaccination education among pregnant women before vaccines are rolled out, especially those who have not received an influenza vaccine within the past year. Improved understanding of willingness to vaccinate among pregnant women will improve future pandemic responses and current vaccination efforts.
C1 [Sznajder, Kristin K.; Kjerulff, Kristen H.; Wang, Ming; Hwang, Wenke] Penn State Univ, Dept Publ Hlth Sci, Coll Med, 90 Hope Dr, Hershey, PA 17033 USA.
   [Ramirez, Sarah, I] Penn State Univ, Dept Family & Community Med, Coll Med, Hershey, PA 17033 USA.
   [Gandhi, Chintan K.] Penn State Univ, Dept Pediat, Coll Med, Hershey, PA 17033 USA.
RP Sznajder, KK (corresponding author), Penn State Univ, Dept Publ Hlth Sci, Coll Med, 90 Hope Dr, Hershey, PA 17033 USA.
EM kek157@psu.edu
OI Gandhi, Chintan/0000-0002-3328-7074
FU Pennsylvania State University Huck Institute of Life Sciences [7754]
FX Acknowledgements Our study was funded by the Pennsylvania State
   University Huck Institute of Life Sciences #7754. We thank the study
   participants for their time.
CR Ahlers-Schmidt CR, 2020, PATIENT EDUC COUNS, V103, P2578, DOI 10.1016/j.pec.2020.09.031
   Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771
   Albrecht M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00555
   [Anonymous], 2020, LANCET, V395, P922, DOI 10.1016/S0140-6736(20)30644-9
   Bodeker B, 2014, VACCINE, V32, P4131, DOI 10.1016/j.vaccine.2014.06.007
   Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596
   Centers for Disease Control and Prevention, 2021, COVID 19 VACC PREGN
   Centers for Disease Control and Prevention, 2021, VACC CONS PEOPL WHO
   Centers for Disease Control and Prevention, COVID 19 VACC US
   Ceulemans M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073367
   Christie A, 2021, MMWR-MORBID MORTAL W, V70, P858, DOI [10.15585/mmwr.mm7023e2, 10.15585/mmwr.mm7023e2externalicon]
   Corace K, 2013, AM J INFECT CONTROL, V41, P679, DOI 10.1016/j.ajic.2013.01.014
   Da Costa D, 1999, J PSYCHOSOM RES, V47, P609, DOI 10.1016/S0022-3999(99)00064-1
   Do TVC, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.16842
   Doroftei B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11040579
   Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI 10.15585/mmwr.mm6925a1externalicon
   Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123
   Fridman D, 2011, AM J OBSTET GYNECOL, V204, pS124, DOI 10.1016/j.ajog.2011.04.011
   Fu C., 2020, ACCEPTANCE PREFERENC, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103]
   Gandhi CK, 2020, AM J INFECT CONTROL, V48, P361, DOI 10.1016/j.ajic.2020.01.010
   Ghiasi N, 2021, IMMUNOPATHOL PERSA, V7, DOI 10.34172/ipp.2021.31
   Gustavson K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45920-7
   Halpin Carmel, 2019, Nurs Older People, V31, P32, DOI 10.7748/nop.2019.e1154
   Hamel L., 2020, KFF COVID 19 VACCINE
   Jamison AM, 2019, SOC SCI MED, V221, P87, DOI 10.1016/j.socscimed.2018.12.020
   Jean-Jacques M, 2021, JAMA-J AM MED ASSOC, V325, P829, DOI 10.1001/jama.2021.1205
   Jung M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200333
   Kadali R.A.K., AM J OBSTET GYNECOL
   Kaiser Family Foundation, COVID 19 COR TRACK U
   Karafillakis E, 2021, VACCINE, V39, P4117, DOI 10.1016/j.vaccine.2021.05.096
   Kerr SM, 2017, ANN EPIDEMIOL, V27, P777, DOI 10.1016/j.annepidem.2017.10.010
   Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x
   Kjerulff KH, 2013, PAEDIATR PERINAT EP, V27, P62, DOI 10.1111/ppe.12014
   Laurence Brian, 2012, J Evid Based Dent Pract, V12, P32, DOI 10.1016/S1532-3382(12)70008-8
   Lean SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186287
   Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210
   MacNeil JR, 2021, MMWR-MORBID MORTAL W, V70, P651, DOI 10.15585/mmwr.mm7017e4
   Mohammed H, 2020, VACCINE, V38, P3358, DOI 10.1016/j.vaccine.2020.02.020
   Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9
   Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2
   Organization W.H., 2021, BACKGR DOC IN VACC S
   Pennsylvania Department of Health, 2019, BIRTH STAT
   Pilishvili T, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2106599
   Power K., 2020, Sustainability: Science, Practice & Policy, V17, P67, DOI 10.1080/15487733.2020.1776561
   Preis H, 2020, SOC SCI MED, V266, DOI 10.1016/j.socscimed.2020.113348
   Rasmussen SA, 2021, OBSTET GYNECOL, V137, P408, DOI 10.1097/AOG.0000000000004290
   Razai M.S., 2021, COVID 19 VACCINE HES
   Razzaghi H, 2021, MMWR-MORBID MORTAL W, V70, P895, DOI [10.1101/2021.03.26.21254402v1, 10.15585/mmwr.mm7024e2]
   Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544
   Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160
   Sarwal Y, 2021, INT J GYNECOL OBSTET, V155, P57, DOI 10.1002/ijgo.13816
   Shimabukuro TT, 2021, NEW ENGL J MED, V384, P2273, DOI 10.1056/NEJMoa2104983
   Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6
   Stoddard J., 2021, CORONAVIRUS IMPACT S
   Thomason M.E., 2020, COPE CORONAVIRUS PER
   Tran VD, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/PharmPract.2021.1.2276, 10.18549/pharmpract.2021.1.2276]
   Verger P, 2020, EXPERT REV VACCINES, V19, P991, DOI 10.1080/14760584.2020.1825945
   Villar J, 2021, JAMA PEDIATR, V175, P817, DOI 10.1001/jamapediatrics.2021.1050
   Waller DK, 2018, BIRTH DEFECTS RES, V110, P342, DOI 10.1002/bdr2.1147
   Hooper MW, 2021, J GEN INTERN MED, V36, P2130, DOI 10.1007/s11606-021-06698-5
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Xu Z, 2019, J COMPUT SOC SCI, V2, P207, DOI 10.1007/s42001-019-00044-w
NR 62
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2211-3355
J9 PREV MED REP
JI Prev. Med. Rep.
PD APR
PY 2022
VL 26
AR 101713
DI 10.1016/j.pmedr.2022.101713
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 0U4PU
UT WOS:000787634200031
PM 35127367
OA gold, Green Published
DA 2022-05-16
ER

PT J
AU Kwok, HF
AF Kwok, Hang Fai
TI Review of Covid-19 vaccine clinical trials ? A puzzle with missing
   pieces
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Review
DE SARS-CoV-2; Pandemic; Vaccination; Different subgroups; Viral Variants
AB A year after the initial outbreak of Covid-19 pandemic, several Phase III clinical trials investigating vaccine safety and efficacy have been published. These vaccine candidates were developed by different research groups and pharmaceutical companies with various vaccine technologies including mRNA, recombinant protein, adenoviral vector and inactivated virus-based platforms. Despite numerous successful clinical trials, participants enrolled in these trials are limited by trial inclusion and exclusion criteria, geographic location and viral outbreak situation. Many questions still remain, especially for specific subgroups, including the elderly, females with pregnancy and breastfeeding status, and adolescents. At the same time, vaccine efficacy towards asymptomatic infection and specific viral variants are still largely unknown. This review will cover vaccine candidates with Phase III clinical trial data released and discuss the scientific data available so far for these vaccine candidates for different subgroups of people and different viral variants.
C1 [Kwok, Hang Fai] Univ Macau, Fac Hlth Sci, Inst Translat Med, Ave Univ, Taipa, Macau, Peoples R China.
RP Kwok, HF (corresponding author), Univ Macau, Fac Hlth Sci, Inst Translat Med, Ave Univ, Taipa, Macau, Peoples R China.
EM hfkwok@um.edu.mo
FU Faculty of Health Sciences (FHS) University of Macau (UM) Faculty
   Allocated Fund (FAF); Science and Technology Development Fund of Macau
   SAR (FDCT) [0055/2019/A1]
FX This study was supported by the Faculty of Health Sciences (FHS)
   University of Macau (UM) Faculty Allocated Fund (FAF) and the Science
   and Technology Development Fund of Macau SAR (FDCT) [0055/2019/A1] to
   HFK. The author thanks Dr. HiuFung Yuen, Prof. Gillian Murphy and Mr.
   Muhammad Jameel Mughal for their critical comments and suggestions on
   the manuscript
CR Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436
   Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389
   Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4
   Caddy S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1790
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Ciabattini A, 2020, SEMIN IMMUNOPATHOL, V42, P619, DOI 10.1007/s00281-020-00821-0
   Cooper DM, 2021, PEDIATR RES, V90, P966, DOI 10.1038/s41390-021-01402-z
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   De Kock JH, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-10070-3
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9
   Graham SP, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00221-3
   Grolli RE, 2021, MOL NEUROBIOL, V58, P1905, DOI 10.1007/s12035-020-02249-x
   Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064
   Haynes BF, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abe0948
   Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920
   Klein SL, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147553
   Ledford H, 2020, NATURE, V588, P377, DOI 10.1038/d41586-020-03542-4
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mellet J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010039
   Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105
   Mukaetova-Ladinska EB, 2021, EUR ARCH PSY CLIN N, V271, P235, DOI 10.1007/s00406-020-01210-2
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1
   Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1
   Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201
   Stamu-O'Brien C, 2020, J COSMET DERMATOL-US, V19, P2169, DOI 10.1111/jocd.13601
   Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8
   Tumban E, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010054
   van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0
   Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1
   Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906
   Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]
   Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]
   Warren RC, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2030033
   Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195
   World Health Organization, DRAFT LANDSC COVID 1
   Wu Kai, 2021, bioRxiv, DOI 10.1101/2021.01.25.427948
   Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740
   Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4
NR 44
TC 8
Z9 9
U1 3
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2021
VL 17
IS 6
BP 1461
EP 1468
DI 10.7150/ijbs.59170
PG 8
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA US7KP
UT WOS:000697605800004
PM 33907509
OA gold, Green Published
DA 2022-05-16
ER

PT J
AU Lefebvre, M
   Vignier, N
   Pitard, B
   Botelho-Nevers, E
   Wyplosz, B
   Cohen, R
   Epaulard, O
AF Lefebvre, M.
   Vignier, N.
   Pitard, B.
   Botelho-Nevers, E.
   Wyplosz, B.
   Cohen, R.
   Epaulard, O.
CA SPILF Vaccination Prevention Grp
TI COVID-19 vaccines: Frequently asked questions and updated answers
SO INFECTIOUS DISEASES NOW
LA English
DT Review
AB At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named COVID-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective antiviral treatment, and mass vaccination came to be considered as the strategy most likely to put an end to the pandemic. The objective of this text is to address and hopefully answer the questions being put forward by healthcare professionals on the different anti-SARS-CoV-2 vaccines as regards their development, their modes of action, their effectiveness, their limits, and their utilization in different situations; we are proposing a report on both today's state of knowledge, and the 14 February 2021 recommendations of the French health authorities.
C1 [Lefebvre, M.] Univ Hotel Dieu, Ctr Hosp, Ctr Prevent Malad Infect & Transmissibles, Serv Malad Infect & Trop,Inserm CIC1413, 1 Pl Alexis Ricordeau, F-44000 Nantes, France.
   [Vignier, N.] Ctr Hosp Andree Rosemon, Ctr Invest Clin Antilles Guyane, CIC Inserm 1424, DRISP, Cayenne, French Guiana.
   [Vignier, N.] Sorbonne Univ, INSERM, IPLESP, Inst Pierre Louis Epidemiol & Sante Publ, F-75012 Paris, France.
   [Pitard, B.] Univ Nantes, CNRS ERL6001, Inserm 1232, CRCINA, Nantes, France.
   [Botelho-Nevers, E.] Univ St Etienne, Ctr Hosp, Serv Infectiol, CIC 1408 Inserm, F-42055 St Etienne, France.
   [Botelho-Nevers, E.] Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol CIRI, Univ Jean Monnet, Univ Lyon,Team GIMAP,INSERM U1111,CNRS,UMR530, F-42023 St Etienne, France.
   [Cohen, R.] Ctr Hosp Intercommunal Creteil, Serv Pediat, InfoVac, 40 Ave Verdun, F-94000 Creteil, France.
   [Epaulard, O.] Univ Grenoble Alpes, Ctr Hosp, Serv Malad Infect, Grenoble, France.
   [Epaulard, O.] CIC 1406 Inserm, Grenoble, France.
   [Vignier, N.] Grp Hosp Sud Ile De France, Dept Infect Dis, F-77000 Melun, France.
   [Wyplosz, B.] Ctr Hosp Univ Bicetre, AP HP, Serv Malad Infect & Trop, Paris, France.
RP Lefebvre, M (corresponding author), Univ Hotel Dieu, Ctr Hosp, Ctr Prevent Malad Infect & Transmissibles, Serv Malad Infect & Trop,Inserm CIC1413, 1 Pl Alexis Ricordeau, F-44000 Nantes, France.
EM naeva.lefebvre@chu-nantes.fr
RI Cohen, Robert/AAM-4426-2021; Vignier, Nicolas/AAH-8382-2021; Epaulard,
   Olivier/AHD-4798-2022
OI Cohen, Robert/0000-0001-6151-0686; Vignier, Nicolas/0000-0002-9410-9327;
   
CR Abu Jabal K, 2021, IMPACT ETHNICITY SEX
   Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), 2021, POINT SIT SURV VACC
   Agence nationale de securite du medicament et des produits de sante (ANSM) Agence nationale de securite du medicament et des produits de sante (ANSM) Agence nationale de securite du medicament et des produits de sante (ANSM) Agence nationale de securite du medicament et des produits de sante (ANSM), 2021, AV ANSM CONC 2 DOS V
   Aley PK, 2021, SAFETY EFFICACY CHAD, V397, P99
   American College of Obstetricians and Gynecologists (ACOG), 2020, VACC PREGN LACT PAT
   Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436
   Bhosle SM, 2018, BIOMATERIALS, V1
   Bhosle SM, 2011, NUCLEIC ACIDS RES, V39, P1595
   Blanchard EL, 2019, MOL THER-NUCL ACIDS, V14, P52, DOI 10.1016/j.omtn.2018.11.002
   Breathnach AS, 2021, J INFECTION, V82, pE11, DOI 10.1016/j.jinf.2021.01.005
   CDC, 2021, INT CLIN CONS US MRN
   CDC,, 2021, VACC CONS PEOPL WHO
   Centre de Reference sur les Agents Teratogenes (CRAT) Centre de Reference sur les Agents Teratogenes (CRAT), 2021, CACC ARNM COV 19 GRO
   Chodick G., 2021, EFFECTIVENESS 1 DOSE, DOI [10.1101/2021.01.27.21250612, DOI 10.1101/2021.01.27.21250612]
   Claro I.M., 2021, GENOMIC CHARACTERISA
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063
   De Befardinrs P, 2020, FRONT IMMUNOL, P21
   Du L., 2020, INFECT DIS THER, V9, P1
   Ebrallifill M, 2019, DAIRY VET SCI J, V11
   Essink, 2021, NEW ENGL J MED, V184, P401
   EVANS DIK, 1990, BRIT MED J, V300, P1694, DOI 10.1136/bmj.300.6741.1694-a
   Fang Wang, 2019, JCI INSIGHT, V1, pE123
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5
   Giegoio E, 2021, P NATL ACAD SCI USA, V1
   Halstead SR, ANTIBODY DEPENDENT E
   Hanrath AT, 2020, J INFECT, DOI [10.1016/ijin12020.12.023, DOI 10.1016/IJIN12020.12.023]
   Haute Autorite de sante (HAS) Haute Autorite de sante (HAS), 2020, STRATEGIC VACCINATIO
   Haute Autorite de sante (HAS) Haute Autorite de sante (HAS), 2021, STRAT VACC SARS COV
   Haute Autorite de sante (HAS) Haute Autorite de sante (HAS) Haute Autorite de sante (HAS) Haute Autorite de sante (HAS), 2021, MOD SCHEM VACC SARS
   Herzog C, 2014, EXPERT REV VACCINES, V13, P399, DOI 10.1586/14760584.2014.883285
   Institut national du cancer (InCA), 2021, PREC PRIOR PAT ATT C
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Johnson WE, 2015, REV VIROL, V2
   Krammer F., 2021, ROBUST SPIKE ANTIBOD, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]
   ladlock TA, ETIOK GY DR RGNOSFS, VI, P93
   LauElIsangHuiKwanChanChiu, 2021, NAT COMMUN, V12, P6
   Lemarchand M, 2020, IND PHARM
   Lemarchand M, 2021, IND PHARM
   Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8
   Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3
   Long Quan-Xin, 2020, Nature Medicine, V26, DOI 10.1038/s41591-020-0965-6
   Longini Pet OV, AD HOCEXPEII GUMP NE
   Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545
   Ma ttachatsa S, 2010, J ADV PHARM TECHNOL, V1, P11
   Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n124
   MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749
   Martiny A-kin BD, 1993, EURJ IMMUNOL VACCINE, V21, P19
   Medicines and Healthcare Products Regulatory Agency Medicines and Healthcare Products Regulatory Agency, 2020, U ASTRAZENECA COV 19
   Ministere des Solidarites et de la Sante Ministere des Solidarites et de la Sante Ministere des Solidarites et de la Sante Ministere des Solidarites et de la Sante, 2021, INT OL VER DEL VACC
   Msomi N., 2020, MEDRXIV, DOI 10.1101/2020.12.21.20248640
   Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Munn I, TRENDS BIOTECHNOL, V2, P94
   Nokleby H, 2006, CURR ALLERGY ASTHM R, V6, P9, DOI 10.1007/s11882-006-0003-x
   Pauli N, NIT REV DRUG LISCOV, V17, P261
   Planning VII, 2020, VACCINES VACCINE, V18, P6191
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Poletto, 2020, EVALUATION STRATEGIE
   Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x
   Rambaut A., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.17.046086, 10.1101/2020.04.17.046086]
   ridhar ti, N ENGL MED
   RiN P, 2017, J ALLERGY CLIN IMMUN, V16, P811
   Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341
   Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5
   Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967
   Societe francaise d'allergologie (SFA) Societe francaise d'allergologie (SFA), 2021, VACC COVID 19
   Societe francaise de rhumatologie (SFR) Societe francaise de rhumatologie (SFR) Societe francaise de rhumatologie (SFR) Societe francaise de rhumatologie (SFR), 2021, VACC COVID 19 PAT AT
   SoniatChook MYM, 2015, BIOCHEMISTRY-US
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0
   Vogel AB., 2020, BIORXIV, DOI 10.1101/2020.09.08.280818.
   Voysey M, 2021, SINGLE DOSE ADM INFL
   Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906
   Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]
   Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195
   Woolsey C, 2021, NAT IMMUNOL, V22, P86, DOI 10.1038/s41590-020-00835-8
   World Health Organization, 2021, DRAFT LANDSC TRACK C
   World Health Organization (WHO) World Health Organization (WHO), 2021, BNT162B2 WHO
   Wu K, 2021, MRNA 1273 CACCINE IN, DOI 10,1101/2021,01.25.427948
NR 81
TC 4
Z9 4
U1 0
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2666-9927
EI 2666-9919
J9 INFECT DIS NOW
JI Infect. Dis. Now
PD JUN
PY 2021
VL 51
IS 4
BP 319
EP 333
DI 10.1016/j.idnow.2021.02.007
EA MAY 2021
PG 15
WC Infectious Diseases
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases
GA SE2AB
UT WOS:000651874700001
PM 33681861
OA Bronze, Green Published
DA 2022-05-16
ER

PT J
AU Paul, E
   Brown, GW
   Kalk, A
   Ridde, V
AF Paul, Elisabeth
   Brown, Garrett W.
   Kalk, Andreas
   Ridde, Valery
TI Playing vaccine roulette: Why the current strategy of staking everything
   on Covid-19 vaccines is a high-stakes wager
SO VACCINE
LA English
DT Editorial Material
ID SEROPREVALENCE; SAFETY
C1 [Paul, Elisabeth] Univ Libre Bruxelles, Sch Publ Hlth, Campus Erasme,Route Lennik 808,CP 591, B-1070 Brussels, Belgium.
   [Brown, Garrett W.] Univ Leeds, Global Hlth Theme, Leeds, W Yorkshire, England.
   [Kalk, Andreas] Deutsch Gesell Int Zusammenarbeit, Kinshasa Country Off, Kinshasa, DEM REP CONGO.
   [Ridde, Valery] Univ Paris, INSERM, Inst Rech Dev IRD, CEPED,IRD, Paris, France.
RP Paul, E (corresponding author), Univ Libre Bruxelles, Sch Publ Hlth, Campus Erasme,Route Lennik 808,CP 591, B-1070 Brussels, Belgium.
EM Elisabeth.Paul@ulb.be; G.W.Brown@leeds.ac.uk; andreas.kalk@giz.de;
   valery.ridde@ird.fr
OI Paul, Elisabeth/0000-0002-3928-4093; Ridde, Valery/0000-0001-9299-8266
CR Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565
   [Anonymous], 2021, PHARMANEWS
   Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2
   Associated Press, 2020, LOS ANGELES TIMES
   Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389
   Bavli I, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4074
   Cambon L, 2021, GLOB HEALTH PROMOT, V28, P3, DOI 10.1177/17579759211015129
   Cardozo T, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13795
   Collateral Global, REG PUBL AN GLOB IMP
   Craig P, 2018, TAKING ACCOUNT CONTE, DOI 10.3310/CIHR-NIHR-01
   Domingo E, 2021, J VIROL, V95, DOI 10.1128/JVI.02437-20
   Doshi P., BMJ OPINION, V2021
   Doshi P, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4037
   Flores LE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37640
   Harrington DP, 2021, NEW ENGL J MED, V384, P576, DOI 10.1056/NEJMe2034294
   He ZY, 2021, LANCET, V397, P1075, DOI 10.1016/S0140-6736(21)00238-5
   Hill Andrew, 2021, Open Forum Infect Dis, V8, pofab358, DOI 10.1093/ofid/ofab358
   Hipgrave DB, 2021, LANCET, V397, P1181, DOI 10.1016/S0140-6736(21)00442-6
   IOANNIDIS JPA, 2021, B WORLD HEALTH ORGAN, V99, P19, DOI [10.1101/2020.05.13.20101253, DOI 10.2471/BLT.20.265892]
   Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715
   Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927
   Kostoff RN, 2020, TOXICOL REP, V7, P1448, DOI 10.1016/j.toxrep.2020.10.016
   Lazarus JV, 2020, NAT MED, V26, P1005, DOI 10.1038/s41591-020-0950-0
   Ledford H., NATURE, V591
   Ledford H, 2021, NATURE, V594, P164, DOI 10.1038/d41586-021-01505-x
   Ledford H, 2020, NATURE, V588, P205, DOI 10.1038/d41586-020-03441-8
   Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8
   Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214
   Mallapaty S., NATURE, V2021
   Mallapaty S, 2021, NATURE, V590, P197, DOI 10.1038/d41586-021-00316-4
   McCartney M, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3473
   Meltzer David O, 2020, medRxiv, DOI 10.1101/2020.05.08.20095893
   Michel J, 2021, GLOBAL HEALTH ACTION, V14, DOI 10.1080/16549716.2021.1927315
   Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x
   Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6
   Paul E, 2020, INT J HEALTH POLICY, DOI 10.34172/ijhpm.2020.240
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Remmel A, 2021, NATURE, V590, P538, DOI 10.1038/d41586-021-00290-x
   Rodriguez Mega E., NATURE, V2021
   Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544
   Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330
   Soulier M, CLIN INFECT DIS PUBL, V2021
   Sturmberg J.P., 2018, HLTH SYSTEM REDESIGN
   Swinburn BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8
   Turcotte-Tremblay AM, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-020-01200-x
   Vaughn VM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11788
   Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1
   Whitmee S, 2015, LANCET, V386, P1973, DOI 10.1016/S0140-6736(15)60901-1
   World Health Organization, VACC IMM
   World Health Organization, 2021, ACC COVID 19 TOOLS F
   Zhou H, NAT COMMUN, V12, P1724
NR 51
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 16
PY 2021
VL 39
IS 35
BP 4921
EP 4924
DI 10.1016/j.vaccine.2021.07.045
EA AUG 2021
PG 4
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA TX3GY
UT WOS:000682979100001
PM 34315610
OA Bronze, Green Published
DA 2022-05-16
ER

PT J
AU Bin Lee, ARY
   Wong, SY
   Chai, LYA
   Lee, SC
   Lee, MX
   Muthiah, MD
   Tay, SH
   Teo, CB
   Tan, BKJ
   Chan, YH
   Sundar, R
   Soon, YY
AF Bin Lee, Ainsley Ryan Yan
   Wong, Shi Yin
   Chai, Louis Yi Ann
   Lee, Soo Chin
   Lee, Matilda Xinwei
   Muthiah, Mark Dhinesh
   Tay, Sen Hee
   Teo, Chong Boon
   Tan, Benjamin Kye Jyn
   Chan, Yiong Huak
   Sundar, Raghav
   Soon, Yu Yang
TI Efficacy of covid-19 vaccines in immunocompromised patients: systematic
   review and meta-analysis
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID RENAL-TRANSPLANT RECIPIENTS; MESSENGER-RNA VACCINE; INFLUENZA
   VACCINATION; SARS-COV-2 VACCINATION; BNT162B2 VACCINATION; HUMORAL
   RESPONSE; PUBLICATION BIAS; IMMUNE-RESPONSE; ANTIBODY; HIV
AB OBJECTIVE
   To compare the efficacy of covid-19 vaccines between immunocompromised and immunocompetent people.
   DESIGN
   Systematic review and meta-analysis.
   DATA SOURCES
   PubMed, Embase, Central Register of Controlled Trials, COVID-19 Open Research Dataset Challenge (CORD-19), and WHO covid-19 databases for studies published between 1 December 2020 and 5 November 2021. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched in November 2021 to identify registered but as yet unpublished or ongoing studies.
   STUDY SELECTION
   Prospective observational studies comparing the efficacy of covid-19 vaccination in immunocompromised and immunocompetent participants.
   METHODS
   A frequentist random effects meta-analysis was used to separately pool relative and absolute risks of seroconversion after the first and second doses of a covid-19 vaccine. Systematic review without meta-analysis of SARS-CoV-2 antibody titre levels was performed after first, second, and third vaccine doses and the seroconversion rate after a third dose. Risk of bias and certainty of evidence were assessed.
   RESULTS
   82 studies were included in the meta-analysis. Of these studies, 77 (94%) used mRNA vaccines, 16 (20%) viral vector vaccines, and 4 (5%) inactivated whole virus vaccines. 63 studies were assessed to be at low risk of bias and 19 at moderate risk of bias. After one vaccine dose, seroconversion was about half as likely in patients with haematological cancers (risk ratio 0.40, 95% confidence interval 0.32 to 0.50, I-2=80%; absolute risk 0.29, 95% confidence interval 0.20 to 0.40, I-2=89%), immune mediated inflammatory disorders (0.53, 0.39 to 0.71, I-2=89%; 0.29, 0.11 to 0.58, I-2=97%), and solid cancers (0.55, 0.46 to 0.65, I-2=78%; 0.44, 0.36 to 0.53, I-2=84%) compared with immunocompetent controls, whereas organ transplant recipients were 16 times less likely to seroconvert (0.06, 0.04 to 0.09, I-2=0%; 0.06, 0.04 to 0.08, I-2=0%). After a second dose, seroconversion remained least likely in transplant recipients (0.39, 0.32 to 0.46, I-2=92%; 0.35, 0.26 to 0.46), with only a third achieving seroconversion. Seroconversion was increasingly likely in patients with haematological cancers (0.63, 0.57 to 0.69, I-2=88%; 0.62, 0.54 to 0.70, I-2=90%), immune mediated inflammatory disorders (0.75, 0.69 to 0.82, I-2=92%; 0.77, 0.66 to 0.85, I-2=93%), and solid cancers (0.90, 0.88 to 0.93, I-2=51%; 0.89, 0.86 to 0.91, I-2=49%). Seroconversion was similar between people with HIV and immunocompetent controls (1.00, 0.98 to 1.01, I-2=0%; 0.97, 0.83 to 1.00, I-2=89%). Systematic review of 11 studies showed that a third dose of a covid-19 mRNA vaccine was associated with seroconversion among vaccine non-responders with solid cancers, haematological cancers, and immune mediated inflammatory disorders, although response was variable in transplant recipients and inadequately studied in people with HIV and those receiving nonmRNA vaccines.
   CONCLUSION
   Seroconversion rates after covid-19 vaccination were significantly lower in immunocompromised patients, especially organ transplant recipients. A second dose was associated with consistently improved seroconversion across all patient groups, albeit at a lower magnitude for organ transplant recipients. Targeted interventions for immunocompromised patients, including a third (booster) dose, should be performed.
C1 [Bin Lee, Ainsley Ryan Yan; Wong, Shi Yin; Teo, Chong Boon; Tan, Benjamin Kye Jyn] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Hlth Syst, Div Infect Dis, Singapore, Singapore.
   [Chai, Louis Yi Ann; Sundar, Raghav; Soon, Yu Yang] Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Singapore, Synthet Biol Clin & Technol Innovat, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Canc Inst, Singapore, Singapore.
   [Lee, Soo Chin; Lee, Matilda Xinwei; Sundar, Raghav] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119228, Singapore.
   [Lee, Soo Chin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.
   [Muthiah, Mark Dhinesh] Natl Univ Hlth Syst, Dept Gastroenterol & ITepatol, Singapore, Singapore.
   [Muthiah, Mark Dhinesh] Natl Univ, Ctr Organ Transplantat, Singapore, Singapore.
   [Tay, Sen Hee] Natl Univ Singapore Hosp, Dept Med, Div Rheumatol, Singapore, Singapore.
   [Chan, Yiong Huak] Natl Univ Singapore, Yong Loo Lin Sch Med, Biostat Unit, Singapore, Singapore.
   [Sundar, Raghav] Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.
   [Sundar, Raghav] Natl Univ Singapore, N1 Inst Hlth, Singapore, Singapore.
   [Sundar, Raghav] Singapore Gastr Canc Consortium, Singapore, Singapore.
   [Soon, Yu Yang] Natl Univ Canc Inst, Dept Radiat Oncol, Singapore, Singapore.
RP Sundar, R (corresponding author), Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.; Sundar, R (corresponding author), Natl Univ Singapore Hosp, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119228, Singapore.; Sundar, R (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.; Sundar, R (corresponding author), Natl Univ Singapore, N1 Inst Hlth, Singapore, Singapore.; Sundar, R (corresponding author), Singapore Gastr Canc Consortium, Singapore, Singapore.
EM mdcragh@nus.edu.sg
OI Tan, Benjamin Kye Jyn/0000-0002-9411-6164
CR Achiron A, 2021, J NEUROIMMUNOL, V361, DOI 10.1016/j.jneuroim.2021.577746
   Achiron A, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211012835
   Agbarya A, 2021, CANCERS, V13, DOI 10.3390/cancers13164191
   Al Samaraee A, 2020, BRIT J HOSP MED, V81, DOI 10.12968/hmed.2020.0191
   Ali A, 2021, VACCINE, V39, P6111, DOI 10.1016/j.vaccine.2021.08.078
   Ali MAM, 2021, TRENDS CARDIOVAS MED, V31, P143, DOI 10.1016/j.tcm.2020.12.004
   American Society of Transplantation International Society for Heart and Lung Transplantation, 2021, JOINT STAT VACC EFF
   Anema A, 2008, HIV MED, V9, P57, DOI 10.1111/j.1468-1293.2008.00515.x
   Apostolidis SA, 2021, NAT MED, V27, P1990, DOI 10.1038/s41591-021-01507-2
   Barriere J, 2021, ANN ONCOL, V32, P1053, DOI 10.1016/j.annonc.2021.04.019
   Beck CR, 2012, J INFECT DIS, V206, P1250, DOI 10.1093/infdis/jis487
   Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339
   Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575
   Bertrand D, 2021, KIDNEY INT, V100, P1337, DOI 10.1016/j.kint.2021.09.014
   Bitoun S, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01183-2
   Boekel L, 2021, LANCET RHEUMATOL, V3, pE778, DOI 10.1016/S2665-9913(21)00222-8
   Canti L, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01190-3
   Catherine FX, 2017, HUM VACC IMMUNOTHER, V13, P1304, DOI 10.1080/21645515.2016.1277844
   Centers for Disease Control and Prevention, COV 19 VACC MOD SEV
   Chavarot N, 2021, AM J TRANSPLANT, V21, P4043, DOI 10.1111/ajt.16814
   Chong PP, 2018, CLIN INFECT DIS, V66, P1802, DOI 10.1093/cid/cix1081
   Chowdhury O, 2021, BRIT J HAEMATOL, V194, P1010, DOI 10.1111/bjh.17644
   Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X
   Crespo M, 2022, AM J TRANSPLANT, V22, P786, DOI 10.1111/ajt.16854
   Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, pE60, DOI 10.1002/art.41928
   D'Offizi G, 2022, LIVER INT, V42, P180, DOI 10.1111/liv.15089
   Danthu C, 2021, J AM SOC NEPHROL, V32, P2154, DOI 10.1681/ASN.2021040490
   Debska-Slizien A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101165
   Deepak P, 2021, ANN INTERN MED, V174, P1572, DOI 10.7326/M21-1757
   Del Bello A, 2022, AM J TRANSPLANT, V22, P322, DOI 10.1111/ajt.16775
   Di Noia V, 2021, CLIN CANCER RES, V27, P6815, DOI 10.1158/1078-0432.CCR-21-2439
   Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eliakim-Raz N, 2021, JAMA ONCOL, V7, P1716, DOI 10.1001/jamaoncol.2021.4390
   Fan YJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090989
   Fathizadeh H, 2021, INT J BIOL MACROMOL, V188, P740, DOI 10.1016/j.ijbiomac.2021.08.076
   Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647
   Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015
   Gavriatopoulou M, 2021, BLOOD ADV, V5, P4398, DOI 10.1182/bloodadvances.2021005444
   Gavriatopoulou M, 2021, CLIN EXP MED, DOI 10.1007/s10238-021-00746-4
   Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272
   Ghione P, 2021, BLOOD, V138, P811, DOI 10.1182/blood.2021012443
   Goshen-Lago T, 2021, JAMA ONCOL, V7, P1507, DOI 10.1001/jamaoncol.2021.2675
   Greenberger LM, 2021, CANCER CELL, V39, P1297, DOI 10.1016/j.ccell.2021.09.001
   Grinshpun A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100283
   Grupper A, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14478
   Grupper A, 2021, AM J TRANSPLANT, V21, P2719, DOI 10.1111/ajt.16615
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Haberman RH, 2021, ANN RHEUM DIS, V80, P1339, DOI 10.1136/annrheumdis-2021-220597
   Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029
   Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462
   Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568
   Tzarfati KH, 2021, AM J HEMATOL, V96, P1195, DOI 10.1002/ajh.26284
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hod T, 2021, TRANSPLANTATION, V105, pE234, DOI 10.1097/TP.0000000000003889
   Iacono D, 2021, J GERIATR ONCOL, V12, P1253, DOI 10.1016/j.jgo.2021.06.002
   Izmirly PM, 2022, ARTHRITIS RHEUMATOL, V74, P284, DOI 10.1002/art.41937
   Jedicke N, 2022, HIV MED, V23, P558, DOI 10.1111/hiv.13202
   Jin PF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00481-y
   Kantauskaite M, 2022, AM J TRANSPLANT, V22, P634, DOI 10.1111/ajt.16851
   Kennedy NA, 2021, GUT, V70, P1884, DOI 10.1136/gutjnl-2021-324789
   Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8
   Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756
   Lee JH, 2020, VACCINE, V38, P3995, DOI 10.1016/j.vaccine.2020.04.022
   Levy I, 2021, CLIN MICROBIOL INFEC, V27, P1851, DOI 10.1016/j.cmi.2021.07.031
   Ligumsky H, 2022, JNCI-J NATL CANCER I, V114, P203, DOI 10.1093/jnci/djab174
   Lim SH, 2021, LANCET HAEMATOL, V8, pE542, DOI 10.1016/S2352-3026(21)00199-X
   Linardou H, 2021, CANCERS, V13, DOI 10.3390/cancers13184621
   Lindemann M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101075
   Liontos M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101148
   Liontos M, 2022, PROSTATE CANCER P D, V25, P117, DOI 10.1038/s41391-021-00455-9
   Livingston Edward H, 2021, JAMA, V325, P898, DOI 10.1001/jama.2021.1375
   Madan A, 2020, CANCER MED-US, V9, P9205, DOI 10.1002/cam4.3534
   Madhi SA, 2021, LANCET HIV, V8, pE568, DOI 10.1016/S2352-3018(21)00157-0
   Mahil SK, 2021, LANCET RHEUMATOL, V3, pE627, DOI 10.1016/S2665-9913(21)00212-5
   Malard F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00534-z
   Manuel O, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13511
   Marasco V, 2022, BRIT J HAEMATOL, V196, P548, DOI 10.1111/bjh.17877
   Marinaki S, 2021, AM J TRANSPLANT, V21, P2913, DOI 10.1111/ajt.16607
   Massarweh A, 2021, JAMA ONCOL, V7, P1133, DOI 10.1001/jamaoncol.2021.2155
   Mazzola A, 2022, CLIN INFECT DIS, V74, P1093, DOI 10.1093/cid/ciab580
   McInnes IB, 2021, NAT REV IMMUNOL, V21, P680, DOI 10.1038/s41577-021-00603-1
   Medeiros-Ribeiro AC, 2021, NAT MED, V27, P1744, DOI 10.1038/s41591-021-01469-5
   Miele M, 2021, AM J TRANSPLANT, V21, P2919, DOI 10.1111/ajt.16702
   Mohammed AH, 2020, AIDS REV, V22, P151, DOI 10.24875/AIDSRev.20000052
   Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8
   Mrak D, 2021, ANN RHEUM DIS, V80, P1345, DOI 10.1136/annrheumdis-2021-220781
   Narasimhan M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070708
   Page MJ, 2021, PLOS MED, V18, DOI [10.1371/journal.pmed.1003583, 10.1016/j.ijsu.2021.105906]
   Palich R, 2021, Ann Oncol, V32, P1294, DOI 10.1016/j.annonc.2021.06.018
   Palich R, 2021, ANN ONCOL, V32, P1051, DOI 10.1016/j.annonc.2021.04.020
   Parry H, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00528-x
   Peeters M, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100274
   Peled Y, 2022, J HEART LUNG TRANSPL, V41, P148, DOI 10.1016/j.healun.2021.08.010
   Peled Y, 2021, J HEART LUNG TRANSPL, V40, P759, DOI 10.1016/j.healun.2021.04.003
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   Pimpinelli F, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01090-6
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Pregliasco F, 1996, VACCINE, V14, P267, DOI 10.1016/0264-410X(95)00209-J
   Prendecki M, 2021, LANCET, V398, P1482, DOI 10.1016/S0140-6736(21)02096-1
   Prendecki M, 2021, ANN RHEUM DIS, V80, P1322, DOI 10.1136/annrheumdis-2021-220626
   Rabinowich L, 2021, J HEPATOL, V75, P435, DOI 10.1016/j.jhep.2021.04.020
   Rahav G, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101158
   Rashidi-Alavijeh J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070738
   Reuken PA, 2022, J CROHNS COLITIS, V16, P251, DOI 10.1093/ecco-jcc/jjab147
   Rincon-Arevalo H, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1031
   Roifman CM, 2021, LYMPHOSIGN J, V8, P37, DOI 10.14785//lymphosign-2021-0020
   Rubbert-Roth A, 2021, LANCET RHEUMATOL, V3, pE470, DOI 10.1016/S2665-9913(21)00186-7
   Ruether DF, 2022, CLIN GASTROENTEROL H, V20, P162, DOI 10.1016/j.cgh.2021.09.003
   Sattler A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150175
   Schmidt T, 2021, AM J TRANSPLANT, V21, P3990, DOI 10.1111/ajt.16818
   Schmiedeberg K, 2022, LANCET RHEUMATOL, V4, pE11, DOI 10.1016/S2665-9913(21)00328-3
   Schramm R, 2021, CLIN RES CARDIOL, V110, P1142, DOI 10.1007/s00392-021-01880-5
   Schrezenmeier E, 2021, J AM SOC NEPHROL, V32, P3027, DOI 10.1681/ASN.2021070966
   Seyahi E, 2021, RHEUMATOL INT, V41, P1429, DOI 10.1007/s00296-021-04910-7
   Shem-Tov N, 2022, BRIT J HAEMATOL, V196, P884, DOI 10.1111/bjh.17918
   Sherman AC, 2021, CLIN INFECT DIS, DOI 10.1093/cid/ciab930
   Shinjo SK, 2021, RHEUMATOLOGY, DOI 10.1093/rheumatology/keab773
   Shmueli ES, 2021, EUR J CANCER, V157, P124, DOI 10.1016/j.ejca.2021.08.007
   Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z
   Silva-Cayetano A, 2021, MED-CAMBRIDGE, V2, P243, DOI 10.1016/j.medj.2020.12.006
   Simon D, 2021, ANN RHEUM DIS, V80, P1312, DOI 10.1136/annrheumdis-2021-220461
   Ssentongo P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85359-3
   Stampfer SD, 2021, LEUKEMIA, V35, P3534, DOI 10.1038/s41375-021-01354-7
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178
   Terpos E, 2021, CANCERS, V13, DOI 10.3390/cancers13174480
   Terpos E, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01099-x
   US Food and Drug Administration, 2021, COR COVID 19 UPD FDA
   Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1
   Westhoff TH, 2021, KIDNEY INT, V100, P1135, DOI 10.1016/j.kint.2021.09.001
   Westra J, 2014, CLIN EXP IMMUNOL, V178, P40, DOI 10.1111/cei.12390
   Wise J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2160
   Woldemeskel BA, 2022, CLIN INFECT DIS, V74, P1268, DOI 10.1093/cid/ciab648
   Wong SY, 2021, GASTROENTEROLOGY, V161, P715, DOI 10.1053/j.gastro.2021.04.025
   Yi Stephanie G, 2021, Transplantation, V105, pe72, DOI 10.1097/TP.0000000000003764
   Zagouri F, 2021, BREAST, V60, P58, DOI 10.1016/j.breast.2021.08.017
   Zbinden D, 2014, IMMUNOTHERAPY-UK, V6, P131, DOI [10.2217/IMT.13.171, 10.2217/imt.13.171]
   Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344
NR 143
TC 3
Z9 3
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
EI 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAR 2
PY 2022
VL 376
AR e068632
DI 10.1136/bmj-2021-068632
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZX8XR
UT WOS:000772178100006
PM 35236664
OA Green Published, Green Submitted, hybrid
DA 2022-05-16
ER

